المؤلفون: Hughes, Gareth, Dark, Paul

المصدر: RECOVERY Collaborative Group , Hughes , G & Dark , P 2024 , ' Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY) : a randomised, controlled, open-label, platform trial ' , The Lancet. Child & adolescent health , vol. 8 , no. 3 , pp. 190-200 . https://doi.org/10.1016/S2352-4642Test(23)00316-4

مصطلحات موضوعية: Humans, Male, Child, Female, COVID-19/complications, SARS-CoV-2, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Immunoglobulins, Intravenous/therapeutic use, Bayes Theorem, Treatment Outcome, Methylprednisolone/therapeutic use, Inflammation, Immunomodulation, Systemic Inflammatory Response Syndrome

الوصف: Background: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment. Methods: We did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK. Eligible patients were younger than 18 years and had been admitted to hospital for PIMS-TS. In the first randomisation, patients were randomly assigned (1:1:1) to usual care (no additional treatments), usual care plus methylprednisolone (10mg/kg per day for 3 consecutive days), or usual care plus intravenous immunoglobulin (a single dose of 2 g/kg). If further anti-inflammatory treatment was considered necessary, children aged at least 1 year could be considered for a second randomisation, in which patients were randomly assigned (1:2:2) to usual care, intravenous tocilizumab (12 mg/kg in patients <30 kg; 8mg/kg in patients ≥30 kg, up to a maximum dose of 800 mg), or subcutaneous anakinra (2 mg/kg once per day in patients ≥10 kg). Randomisation was by use of a web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was duration of hospital stay. Analysis was by intention to treat. For treatments assessed in each randomisation, a single Bayesian framework assuming uninformative priors for treatment was used to jointly assess the efficacy of each intervention compared with usual care. The trial was registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between May 18, 2020, and Jan 20, 2022, 237 children with PIMS-TS were enrolled and included in the ...

العلاقة: https://research.manchester.ac.uk/en/publications/4c324435-1ff8-4b23-b729-558db148d055Test

الإتاحة: https://doi.org/10.1016/S2352-4642Test(23)00316-4
https://research.manchester.ac.uk/en/publications/4c324435-1ff8-4b23-b729-558db148d055Test

المؤلفون: Ludwig, Heinz, Terpos, Evangelos, van de Donk, Niels, Mateos, Maria-Victoria, Moreau, Philippe, Dimopoulos, Melitios-Athanasios, Delforge, Michel, Rodriguez-Otero, Paula, San-Miguel, Jesús, Yong, Kwee, Gay, Francesca, Einsele, Hermann, Mina, Roberto, Caers, Jo, Driessen, Christoph, Musto, Pellegrino, Zweegman, Sonja, Engelhardt, Monika, Cook, Gordon, Weisel, Katja, Broijl, Annemiek, Beksac, Meral, Bila, Jelena, Schjesvold, Fredrik, Cavo, Michele, Hajek, Roman, Touzeau, Cyrille, Boccadoro, Mario, Sonneveld, Pieter

المصدر: The Lancet Oncology, 24 (6), e255 - e269 (2023-06)

مصطلحات موضوعية: cell-associated neurotoxicity, Antibodies, Bispecific, Interleukin 1 Receptor Antagonist Protein, Humans, Cytokine Release Syndrome/etiology, Cytokine Release Syndrome/prevention & control, Cytokine Release Syndrome/drug therapy, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Consensus, Immunotherapy, Adoptive/adverse effects, T-Lymphocytes, Multiple Myeloma/drug therapy, Antibodies, Bispecific/adverse effects, Cytokine Release Syndrome, Immunotherapy, Adoptive, Multiple Myeloma, Oncology, Human health sciences, Hematology, Sciences de la santé humaine, Hématologie

الوصف: T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, hypogammaglobulinaemia, and infections are common. This Policy Review presents a consensus from the European Myeloma Network on the prevention and management of these adverse events. Recommended measures include premedication, frequent assessing for symptoms and severity of cytokine release syndrome, step-up dosing for several BsAbs and some CAR T-cell therapies; corticosteroids; and tocilizumab in the case of cytokine release syndrome. Other anti-IL-6 drugs, high-dose corticosteroids, and anakinra might be considered in refractory cases. ICANS often arises concomitantly with cytokine release syndrome. Glucocorticosteroids in increasing doses are recommended if needed, as well as anakinra if the response is inadequate, and anticonvulsants if convulsions occur. Preventive measures against infections include antiviral and antibacterial drugs and administration of immunoglobulins. Treatment of infections and other complications is also addressed.

العلاقة: https://api.elsevier.com/content/article/PII:S1470204523001596?httpAccept=text/xmlTest; urn:issn:1470-2045; urn:issn:1474-5488

الوصول الحر: https://orbi.uliege.be/handle/2268/310482Test

المؤلفون: Audemard-Verger, Alexandra, Le Gouge, Amélie, Pestre, Vincent, Courjon, Johan, Langlois, Vincent, Vareil, Marc-Olivier, Devaux, Mathilde, Bienvenu, Boris, Leroy, Vincent, Goulabchand, Radjiv, Colombain, Léa, Bigot, Adrien, Guimard, Thomas, Douadi, Youcef, Urbanski, Geoffrey, Faucher, Jean-François, Maulin, Laurence, Lioger, Bertrand, Talarmin, Jean-Philippe, Groh, Matthieu, Emmerich, Joseph, Deriaz, Sophie, Ferreira-Maldent, Nicole, Cook, Ann-Rose, Lengellé, Céline, Bourgoin, Hélène, Mékinian, Arsène, Aouba, Achille, Maillot, François, Caille, Agnès

المساهمون: Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Tours (UT), Centre d’Investigation Clinique Tours CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Henri Duffaut (Avignon), Service d'infectiologie CHU Nice, Centre Hospitalier Universitaire de Nice (CHU Nice), Groupe Hospitalier du Havre Hôpital Jacques Monod (MONTIVILLIERS) (GHH), Centre Hospitalier de la Côte Basque (CHCB), Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS Poissy, Hôpital Saint-Joseph Marseille, Clinique Teissier (Valenciennes) (AHNAC), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service des Maladies Infectieuses et Tropicales, Centre Hospitalier de Perpignan, Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre hospitalier de Saint-Quentin, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service des Maladies infectieuses et tropicales CHU Limoges, CHU Limoges, Epidémiologie des Maladies Chroniques en zone tropicale (EpiMaCT), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-OmégaHealth (ΩHealth), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), CH du Pays d'Aix, Aix-en-Provence, Centre Hospitalier de Blois (CHB), CH de Quimper, Hôpital Foch Suresnes, Groupe Hospitalier Paris Saint-Joseph (hpsj), Centre for Research in Epidemiology and Statistics, Conservatoire National des Arts et Métiers CNAM (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Pharmacologie CHRU Tours, CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)

المصدر: ISSN: 1932-6203.

مصطلحات موضوعية: MESH: Adult, MESH: COVID-19 Drug Treatment, MESH: Humans, MESH: Interleukin 1 Receptor Antagonist Protein / adverse effects, MESH: Interleukin 1 Receptor Antagonist Protein / therapeutic use, MESH: Respiration, Artificial, MESH: SARS-CoV-2, MESH: Treatment Outcome, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: International audience ; Objective: we aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients. Methods: in this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen. We randomly assigned patients to receive intravenous anakinra plus optimized standard of care (oSOC) vs. oSOC alone. The primary outcome was treatment success at day 14 defined as patient alive and not requiring mechanical ventilation or extracorporeal membrane oxygenation.Results: between 27th April and 6th October 2020, we enrolled 71 patients (240 patients planned to been enrolled): 37 were assigned to the anakinra group and 34 to oSOC group. The study ended prematurely by recommendation of the data and safety monitoring board due to safety concerns. On day 14, the proportion of treatment success was significantly lower in the anakinra group 70% (n=26) vs. 91% (n=31) in the oSOC group: risk difference -21 percentage points (95% CI, -39 to -2), odds ratio 0.23 (95% CI, 0.06 to 0.91), p=0.027. After a 28-day follow-up, 9 patients in the anakinra group and 3 in the oSOC group had died. Overall survival at day 28 was 75% (95% CI, 62% to 91%) in the anakinra group versus 91% (95% CI, 82% to 100%) (p=0.06) in the oSOC group. Serious adverse events occurred in 19 (51%) patients in the anakinra group and 18 (53%) in the oSOC group (p=0·89).

العلاقة: hal-04064443; https://hal.science/hal-04064443Test; https://hal.science/hal-04064443/documentTest; https://hal.science/hal-04064443/file/journal.pone.0269065.pdfTest

الإتاحة: https://doi.org/10.1371/journal.pone.0269065Test
https://hal.science/hal-04064443Test
https://hal.science/hal-04064443/documentTest
https://hal.science/hal-04064443/file/journal.pone.0269065.pdfTest

المؤلفون: Durdzińska Timóteo, A., Dumusc, A., Durand, S.

المصدر: Hand surgery & rehabilitation, vol. 41, no. 6, pp. 701-706

مصطلحات موضوعية: Humans, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Wrist, Calcium, Retrospective Studies, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Pain, Anakinra, Basic calcium phosphate, Blocage IL-1, Calcific periarthritis, Hand, IL-1 blockade, Main, Phosphate de calcium basique, Périarthrite calcifiante, Ultrasons, Ultrasound

الوصف: Acute calcium deposit (ACD) in the hand and wrist is a cause of acute pain due to crystal-induced soft-tissue inflammation. There are no standard management guidelines for this condition, which is frequently treated with non-steroidal anti-inflammatory drugs (NSAIDs), with variable efficacy, some patients presenting symptoms for several months. We retrospectively analyzed the results of all patients treated with anakinra for hand or wrist ACD in our department in 2020. We extracted data on treatment duration, pain, range of motion, skin erythema, hypervascularization, edema, and X-ray findings. Ten patients were treated for hand or wrist ACD with anakinra 100 mg per day for a mean 2.7 days. We observed rapid and significant improvement in pain, range of motion, local erythema and edema from day 2 and a decrease in skin temperature from day 3. Calcifications significantly decreased in size or disappeared in the majority of the patients. There were no adverse events or recurrences at 1 year's follow-up. Anakinra was associated with significant clinical improvement after only two days' treatment and may be considered to treat patients with hand or wrist ACD, especially in case of contraindications to NSAIDs or glucocorticoids. Further controlled studies are needed to confirm the present observations.

وصف الملف: application/pdf

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36087874; info:eu-repo/semantics/altIdentifier/eissn/2468-1210; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_437E3B239CC31; https://serval.unil.ch/notice/serval:BIB_437E3B239CC3Test; urn:issn:2468-1210; https://serval.unil.ch/resource/serval:BIB_437E3B239CC3.P001/REF.pdfTest; http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_437E3B239CC31Test

الإتاحة: https://doi.org/10.1016/j.hansur.2022.08.009Test
https://serval.unil.ch/notice/serval:BIB_437E3B239CC3Test
https://serval.unil.ch/resource/serval:BIB_437E3B239CC3.P001/REF.pdfTest
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_437E3B239CC31Test

المؤلفون: Mikkelsen, Rasmus R, Hundahl, Malthe P, Torp, Christopher K, Rodríguez-Carrio, Javier, Kjolby, Mads, Bruun, Jens M, Kragstrup, Tue W

المصدر: Mikkelsen , R R , Hundahl , M P , Torp , C K , Rodríguez-Carrio , J , Kjolby , M , Bruun , J M & Kragstrup , T W 2022 , ' Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus : A bedside-to-bench approach ' , European Journal of Pharmacology , vol. 925 , 174998 . https://doi.org/10.1016/j.ejphar.2022.174998Test

مصطلحات موضوعية: Animals, Cardiovascular Diseases/drug therapy, Colchicine, Diabetes Mellitus, Type 2/complications, Etanercept/pharmacology, Humans, Hydroxychloroquine/therapeutic use, Immunosuppression Therapy, Inflammation/chemically induced, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Methotrexate/therapeutic use, Sulfasalazine/therapeutic use, Hydroxychloroquine/pharmacology, Immunomodulating Agents/pharmacology, Sulfasalazine/pharmacology, Colchicine/pharmacology, Interleukin-1/antagonists & inhibitors, Type 2/drug therapy, Interleukin 1 Receptor Antagonist Protein/pharmacology, Interleukin-1beta/antagonists & inhibitors, Antibodies, Monoclonal, Humanized/pharmacology, Immunosuppressive Agents/pharmacology, Inflammation/drug therapy, Methotrexate/pharmacology

الوصف: OBJECTIVE: To assess which immunosuppressive drugs have been investigated and proven efficacious in patients with cardiovascular disease (CVD) or type 2 diabetes (T2D) without preexisting immune mediated disorders to validate in vitro and animal model findings on low grade inflammation (bedside-to-bench). METHODS: Clinical trials on immunosuppressive drugs in CVD or T2D were found in PubMed. Studies on patients with preexisting immune mediated inflammatory disease were excluded. A total of 19 clinical trials testing canakinumab, anakinra, methotrexate, colchicine, hydroxychloroquine, etanercept and sulfasalazine were found. RESULTS: Canakinumab and colchicine significantly reduced the risk of CVD, whereas methotrexate did not. Sulfasalazine showed no effect on vascular function. Anakinra and hydroxychloroquine had a positive effect on glycemic control and β-cell function in T2D. Etanercept had no effect in patients with T2D. CONCLUSION: The observed results indicate that immunosuppressive drugs specifically targeting IL-1β hold promise for dampening CVD and T2D. These findings validate in vitro and animal models showing involvement of the IL-1-axis in the pathogenesis of CVD and T2D. The use of immunosuppressive drugs targeting the chronic inflammation in these diseases could be a possible future treatment strategy as an add-on to the existing pharmacological treatment of CVD and T2D. However, potential treatment effects, adverse events and cost-effectiveness should be carefully considered with importance for drug development.

وصف الملف: application/pdf

العلاقة: https://pure.au.dk/portal/da/publications/immunomodulatory-and-immunosuppressive-therapies-in-cardiovascular-disease-and-type-2-diabetes-mellitusTest(89dc7ad3-f029-46e6-b0e6-b29b06deb44c).html

الإتاحة: https://doi.org/10.1016/j.ejphar.2022.174998Test
https://pure.au.dk/portal/da/publications/immunomodulatory-and-immunosuppressive-therapies-in-cardiovascular-disease-and-type-2-diabetes-mellitusTest(89dc7ad3-f029-46e6-b0e6-b29b06deb44c).html
https://pure.au.dk/ws/files/352590179Test/1-s2.0-S001429992200259X-main.pdf

المساهمون: Jae Seok Kim, Jun Young Lee, Jae Won Yang, Keum Hwa Lee, Maria Effenberger, Wladimir Szpirt, Andreas Kronbichler, Jae Il Shin, Shin, Jae Il

مصطلحات موضوعية: Anti-Inflammatory Agents / pharmacology, Anti-Inflammatory Agents / therapeutic use, Antibodies, Monoclonal, Humanized / pharmacology, Humanized / therapeutic use, Azetidines / pharmacology, Azetidines / therapeutic use, COVID-19 / complications, COVID-19 / drug therapy, COVID-19 / immunology, COVID-19 / virology, Clinical Trials as Topic, Cytokine Release Syndrome / drug therapy, Cytokine Release Syndrome / immunology, Cytokines / antagonists & inhibitors, Cytokines / immunology, Cytokines / metabolism, Humans, Immunosuppressive Agents / pharmacology, Immunosuppressive Agents / therapeutic use, Interleukin 1 Receptor Antagonist Protein / pharmacology, Interleukin 1 Receptor Antagonist Protein / therapeutic use, Janus Kinases / antagonists & inhibitors, Janus Kinases / metabolism, Purines / pharmacology, Purines / therapeutic use, Pyrazoles / pharmacology, Pyrazoles / therapeutic use, SARS-CoV-2 / immunology

الوصف: Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine storm refers to a set of clinical conditions caused by excessive immune reactions and has been recognized as a leading cause of severe COVID-19. While comparisons have been made between COVID-19 cytokine storm and other kinds of cytokine storm such as hemophagocytic lymphohistiocytosis and cytokine release syndrome, the pathogenesis of cytokine storm has not been clearly elucidated yet. Recent studies have shown that impaired response of type-1 IFNs in early stage of COVID-19 infection played a major role in the development of cytokine storm, and various cytokines such as IL-6 and IL-1 were involved in severe COVID-19. Furthermore, many clinical evidences have indicated the importance of anti-inflammatory therapy in severe COVID-19. Several approaches are currently being used to treat the observed cytokine storm associated with COVID-19, and expectations are especially high for new cytokine-targeted therapies, such as tocilizumab, anakinra, and baricitinib. Although a number of studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made on which drugs should be used for which patients and when. In this review, we provide an overview of cytokine storm in COVID-19 and treatments currently being used to address it. In addition, we discuss the potential therapeutic role of extracorporeal cytokine removal to treat the cytokine storm associated with COVID-19. ; open

العلاقة: THERANOSTICS; J03103; OAK-2021-01759; https://ir.ymlib.yonsei.ac.kr/handle/22282913/181964Test; T202100024; THERANOSTICS, Vol.11(1) : 316-329, 2021-01

الإتاحة: https://doi.org/10.7150/thno.49713Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/181964Test

المؤلفون: Liu, Johnson M, Chi, Jeffrey

المصدر: Maine Medical Center

مصطلحات موضوعية: COVID-19, Cytokines, hemophagocytic lymphohistiocytosis, immunobiology, immunology/microbiology/virology, inflammation, Antibodies, Monoclonal (therapeutic use), Neutralizing (therapeutic use), COVID-19 (complications), Cytokine Release Syndrome (etiology, therapy, virology), Humans, Interleukin 1 Receptor Antagonist Protein (therapeutic use), Lymphohistiocytosis, Hemophagocytic (diagnosis, etiology, immunology, therapy)

الوصف: Cytokine storm is an umbrella term that describes an inflammatory syndrome characterized by elevated levels of circulating cytokines and hyperactivation of innate and/or adaptive immune cells. One type of cytokine storm is hemophagocytic lymphohistiocytosis (HLH), which can be either primary or secondary. Severe COVID-19-associated pneumonia and acute respiratory distress syndrome (ARDS) can also lead to cytokine storm/cytokine release syndrome (CS/CRS) and, more rarely, meet criteria for the diagnosis of secondary HLH. Here, we review the immunobiology of primary and secondary HLH and examine whether COVID-19-associated CS/CRS can be discriminated from non-COVID-19 secondary HLH. Finally, we review differences in immunobiology between these different entities, which may inform both clinical diagnosis and treatment of patients.

العلاقة: https://knowledgeconnection.mainehealth.org/mmc/2223Test; https://pubmed.ncbi.nlm.nih.gov/35068219Test/

الإتاحة: https://knowledgeconnection.mainehealth.org/mmc/2223Test
https://pubmed.ncbi.nlm.nih.gov/35068219Test/

المؤلفون: Rasmus R. Mikkelsen, Malthe P. Hundahl, Christopher K. Torp, Javier Rodríguez-Carrio, Mads Kjolby, Jens M. Bruun, Tue W. Kragstrup

المصدر: Scopus
Mikkelsen, R R, Hundahl, M P, Torp, C K, Rodríguez-Carrio, J, Kjolby, M, Bruun, J M & Kragstrup, T W 2022, ' Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus : A bedside-to-bench approach ', European Journal of Pharmacology, vol. 925, 174998 . https://doi.org/10.1016/j.ejphar.2022.174998Test

مصطلحات موضوعية: Inflammation/chemically induced, Methotrexate/therapeutic use, Sulfasalazine/therapeutic use, Interleukin-1beta, Antibodies, Monoclonal, Humanized, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Etanercept, Immunomodulating Agents, Animals, Humans, Immunosuppression Therapy, Inflammation, Pharmacology, Diabetes Mellitus, Type 2/complications, Etanercept/pharmacology, Sulfasalazine, Interleukin 1 Receptor Antagonist Protein, Methotrexate, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Hydroxychloroquine/therapeutic use, Cardiovascular Diseases/drug therapy, Colchicine, Immunosuppressive Agents, Hydroxychloroquine, Interleukin-1

الوصف: OBJECTIVE: To assess which immunosuppressive drugs have been investigated and proven efficacious in patients with cardiovascular disease (CVD) or type 2 diabetes (T2D) without preexisting immune mediated disorders to validate in vitro and animal model findings on low grade inflammation (bedside-to-bench).METHODS: Clinical trials on immunosuppressive drugs in CVD or T2D were found in PubMed. Studies on patients with preexisting immune mediated inflammatory disease were excluded. A total of 19 clinical trials testing canakinumab, anakinra, methotrexate, colchicine, hydroxychloroquine, etanercept and sulfasalazine were found.RESULTS: Canakinumab and colchicine significantly reduced the risk of CVD, whereas methotrexate did not. Sulfasalazine showed no effect on vascular function. Anakinra and hydroxychloroquine had a positive effect on glycemic control and β-cell function in T2D. Etanercept had no effect in patients with T2D.CONCLUSION: The observed results indicate that immunosuppressive drugs specifically targeting IL-1β hold promise for dampening CVD and T2D. These findings validate in vitro and animal models showing involvement of the IL-1-axis in the pathogenesis of CVD and T2D. The use of immunosuppressive drugs targeting the chronic inflammation in these diseases could be a possible future treatment strategy as an add-on to the existing pharmacological treatment of CVD and T2D. However, potential treatment effects, adverse events and cost-effectiveness should be carefully considered with importance for drug development.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f756fa0c7d520da4cd8a98288ea820dTest
http://hdl.handle.net/10651/65535Test

المؤلفون: Caroline Vinit, Sophie Georgin-Lavialle, Aikaterini Theodoropoulou, Catherine Barbier, Alexandre Belot, Manel Mejbri, Pascal Pillet, Jana Pachlopnik, Sylvaine Poignant, Charlotte Rebelle, Andreas Woerner, Isabelle Koné-Paut, Véronique Hentgen

المساهمون: Centre Hospitalier de Versailles André Mignot (CHV), Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Lausanne University Hospital, Centre Hospitalier Universitaire [Grenoble] (CHU), Service de néphrologie, rhumatologie et dermatologie pédiatriques [Hôpital Femme Mère Enfant, HCL], Hospices Civils de Lyon (HCL)-Hôpital Mère Enfant, CHU Bordeaux [Bordeaux], Département de pédiatrie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), CHU de Bordeaux Pellegrin [Bordeaux], University Children’s Hospital Basel = Hôpital pédiatrique universitaire des deux Bâle [Bâle, Suisse] (UKBB), Service de Rhumatologie [CHU Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre

المصدر: Frontiers in Immunology, Vol 12 (2021)
Frontiers in immunology, vol. 12, pp. 744780
Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2021, 12, ⟨10.3389/fimmu.2021.744780⟩

مصطلحات موضوعية: Male, Familial Mediterranean fever, interleukin-1 blockers, Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized/therapeutic use, Antirheumatic Agents/therapeutic use, Child, Child, Preschool, Female, Hereditary Autoinflammatory Diseases/complications, Hereditary Autoinflammatory Diseases/drug therapy, Humans, Infant, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Interleukin-1/antagonists & inhibitors, Middle Aged, Retrospective Studies, Young Adult, anakinra, autoinflammatory diseases, canakinumab, hereditary recurrent fevers, indications, treatment, 0302 clinical medicine, Quality of life, Immunology and Allergy, Original Research, 0303 health sciences, Mevalonate kinase deficiency, Interleukin, 3. Good health, Antirheumatic Agents, [SDV.IMM]Life Sciences [q-bio]/Immunology, medicine.drug, medicine.medical_specialty, Immunology, MEDLINE, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Internal medicine, medicine, 030304 developmental biology, 030203 arthritis & rheumatology, Anakinra, business.industry, Hereditary Autoinflammatory Diseases, RC581-607, medicine.disease, Canakinumab, Interleukin 1 Receptor Antagonist Protein, Immunologic diseases. Allergy, Complication, business, Interleukin-1

الوصف: BackgroundInterleukin (IL)-1 inhibitors represent the main treatment in patients with colchicine-resistant/intolerant familial Mediterranean fever (crFMF), mevalonate kinase deficiency (MKD), and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). However, the reasons for the use of IL-1 inhibitors in these diseases are still not completely clarified.ObjectiveIdentify real-life situations that led to initiating anakinra or canakinumab treatment in hereditary recurrent fevers (HRFs), combining data from an international registry and an up-to-date literature review.Patients and MethodsData were extracted from the JIRcohort, in which clinical information (demographic data, treatment, disease activity, and quality of life) on patients with FMF, MKD, and TRAPS was retrospectively collected. A literature search was conducted using Medline, EMBASE, and Cochrane databases.ResultsComplete data of 93 patients with HRF (53.8% FMF, 31.2% MKD, and 15.1% TRAPS) were analyzed. Data from both the registry and the literature review confirmed that the main reasons for use of IL-1 blockers were the following: failure of previous treatment (n = 57, 61.3% and n = 964, 75.3%, respectively), persistence of disease activity with frequent attacks (n = 44, 47.3% and n = 1,023, 79.9%) and/or uncontrolled inflammatory syndrome (n = 46, 49.5% and n = 398, 31.1%), severe disease complication or associated comorbidities (n = 38, 40.9% and n = 390, 30.4%), and worsening of patients’ quality of life (n = 36, 38.7% and n = 100, 7,8%). No reasons were specified for 12 (16.4%) JIRcohort patients and 154 (12%) patients in the literature.ConclusionIn the absence of standardized indications for IL-1 inhibitors in crFMF, MKD, and TRAPS, these results could serve as a basis for developing a treat-to-target strategy that would help clinicians codify the therapeutic escalation with IL-1 inhibitors.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e625e3774c42c4cbcb268ba3e8a594dTest
https://www.frontiersin.org/articles/10.3389/fimmu.2021.744780/fullTest

المؤلفون: Idorn, Lars, Vissing, Nadja Hawwa, Jensen, Lise, Herlin, Troels

المصدر: Ugeskrift for Laeger. 174(22):1537